Free Trial

GoodRx (GDRX) Financials

GoodRx logo
$2.92 0.00 (0.00%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$2.83 -0.09 (-3.08%)
As of 08:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for GoodRx

Annual Income Statements for GoodRx

This table shows GoodRx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
14 66 -294 -25 -33 -8.87 16 30
Consolidated Net Income / (Loss)
44 76 -294 -25 -33 -8.87 16 30
Net Income / (Loss) Continuing Operations
44 76 -294 -25 -33 -8.87 16 30
Total Pre-Tax Income
52 83 -303 -10 -23 -56 31 57
Total Operating Income
77 140 -276 13 1.74 -27 66 87
Total Gross Profit
243 374 521 699 701 683 744 739
Total Revenue
250 388 551 745 767 750 792 797
Operating Revenue
250 388 551 745 767 750 792 797
Total Cost of Revenue
6.04 14 30 47 65 67 48 58
Operating Cost of Revenue
6.04 14 30 47 65 67 48 58
Total Operating Expenses
166 235 797 685 700 710 678 652
Selling, General & Admin Expense
8.36 15 461 155 145 126 118 114
Marketing Expense
104 177 255 370 358 341 367 332
Research & Development Expense
44 29 62 126 143 136 124 121
Depreciation Expense
9.81 14 18 35 54 108 70 85
Total Other Income / (Expense), net
-25 -57 -28 -24 -25 -29 -34 -31
Interest Expense
25 54 28 24 34 57 55 43
Interest & Investment Income
0.15 0.72 0.16 0.06 9.27 32 23 11
Other Income / (Expense), net
-0.01 -2.97 -0.02 0.00 0.00 -4.01 -2.66 0.72
Income Tax Expense
8.56 17 -9.83 15 9.60 -47 15 26
Basic Earnings per Share
$0.12 $0.19 ($1.07) ($0.06) ($0.08) ($0.02) $0.04 $0.09
Weighted Average Basic Shares Outstanding
111.84M 226.61M 274.70M 409.98M 412.86M 410.32M 385.74M 356.33M
Diluted Earnings per Share
$0.12 $0.18 ($1.07) ($0.06) ($0.08) ($0.02) $0.04 $0.09
Weighted Average Diluted Shares Outstanding
118.34M 231.21M 274.70M 409.98M 412.86M 410.32M 392.17M 356.97M
Weighted Average Basic & Diluted Shares Outstanding
- - 392.13M 400.85M 397.57M 395.00M 383.61M 342.57M

Quarterly Income Statements for GoodRx

This table shows GoodRx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
-38 -26 -1.01 6.69 3.97 6.74 11 13 1.12 5.43 1.17
Consolidated Net Income / (Loss)
-38 -26 -1.01 6.69 3.97 6.74 11 13 1.12 5.43 1.17
Net Income / (Loss) Continuing Operations
-38 -26 -1.01 6.69 3.97 6.74 11 13 1.12 5.43 1.17
Total Pre-Tax Income
-47 -25 0.29 12 8.11 11 17 20 6.10 14 5.64
Total Operating Income
-38 -18 7.38 20 20 18 23 27 15 23 14
Total Gross Profit
161 181 185 189 184 175 190 190 183 177 174
Total Revenue
180 197 198 201 195 199 203 203 196 195 194
Operating Revenue
180 197 198 201 195 199 203 203 196 195 194
Total Cost of Revenue
19 15 12 12 12 24 13 13 13 17 20
Operating Cost of Revenue
19 15 12 12 12 - 13 13 13 17 20
Total Operating Expenses
200 200 178 169 163 157 166 163 168 155 160
Selling, General & Admin Expense
35 30 41 28 26 24 30 28 32 24 27
Marketing Expense
92 94 90 93 90 94 85 85 84 79 81
Research & Development Expense
40 32 31 31 30 32 31 30 31 29 30
Depreciation Expense
33 44 16 17 18 19 21 20 21 23 22
Total Other Income / (Expense), net
-8.27 -6.35 -7.09 -8.23 -12 -6.77 -6.71 -7.23 -8.52 -8.49 -8.37
Interest Expense
15 15 15 15 14 11 11 11 11 10 9.77
Interest & Investment Income
8.65 8.47 7.56 6.33 4.80 4.59 3.93 2.80 2.31 1.89 1.40
Income Tax Expense
-8.11 1.23 1.30 4.95 4.15 4.67 5.62 6.73 4.98 8.77 4.47
Basic Earnings per Share
($0.09) ($0.06) $0.00 $0.02 $0.01 $0.01 $0.03 $0.04 $0.00 $0.02 $0.00
Weighted Average Basic Shares Outstanding
413.44M 410.32M 390.05M 376.25M 379.67M 385.74M 379.20M 356.62M 346.78M 356.33M 340.53M
Diluted Earnings per Share
($0.09) ($0.06) $0.00 $0.02 $0.01 $0.01 $0.03 $0.04 $0.00 $0.02 $0.00
Weighted Average Diluted Shares Outstanding
413.44M 410.32M 390.05M 384.73M 388.50M 392.17M 379.66M 357.16M 347.81M 356.97M 341.42M
Weighted Average Basic & Diluted Shares Outstanding
406.13M 395.00M 375.21M 379.45M 381.14M 383.61M 357.17M 347.45M 339.43M 342.57M 338.68M

Annual Cash Flow Statements for GoodRx

This table details how cash moves in and out of GoodRx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
17 -19 946 -30 -184 -85 -224 -187
Net Cash From Operating Activities
45 83 131 179 147 138 184 168
Net Cash From Continuing Operating Activities
45 73 131 179 147 138 184 168
Net Income / (Loss) Continuing Operations
44 66 -294 -25 -33 -8.87 16 30
Consolidated Net Income / (Loss)
44 66 -294 -25 -33 -8.87 16 30
Depreciation Expense
9.81 14 18 35 54 108 70 85
Amortization Expense
1.24 3.38 3.39 3.45 3.41 3.38 2.50 1.77
Non-Cash Adjustments To Reconcile Net Income
4.62 -1.29 444 163 125 107 98 9.66
Changes in Operating Assets and Liabilities, net
-14 -8.39 -41 3.46 -2.73 -71 -2.36 41
Net Cash From Investing Activities
-3.46 -37 -92 -179 -210 -56 -70 -120
Net Cash From Continuing Investing Activities
-3.46 -37 -92 -179 -210 -56 -70 -120
Purchase of Property, Plant & Equipment
-3.46 -5.75 -36 -34 -55 -56 -70 -74
Acquisitions
0.00 -31 -56 -140 -157 0.00 0.00 -43
Other Investing Activities, net
- 0.00 0.00 -4.01 -15 0.00 0.00 -2.50
Net Cash From Financing Activities
-25 -55 906 -31 -120 -167 -337 -234
Net Cash From Continuing Financing Activities
-25 -55 906 -31 -120 -167 -337 -234
Repayment of Debt
-321 -214 -36 -7.03 -7.03 -5.27 -642 -5.00
Repurchase of Common Equity
0.00 0.00 -4.94 0.00 -102 -104 -159 -216
Issuance of Debt
902 155 28 - 0.00 0.00 472 0.00
Issuance of Common Equity
0.00 1.62 992 0.00 0.00 1.39 1.77 1.31
Other Financing Activities, net
3.35 3.04 -73 -23 -11 -60 -11 -14
Cash Interest Paid
19 48 25 20 31 49 55 41
Cash Income Taxes Paid
12 19 29 -18 4.36 17 24 13

Quarterly Cash Flow Statements for GoodRx

This table details how cash moves in and out of GoodRx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
33 -123 -139 -8.39 -101 25 -147 -20 -7.79 -12 -26
Net Cash From Operating Activities
60 16 43 9.70 87 45 9.41 50 76 33 12
Net Cash From Continuing Operating Activities
60 16 43 9.70 87 45 9.41 50 76 33 12
Net Income / (Loss) Continuing Operations
-38 -26 -1.01 6.69 3.97 6.74 11 13 1.12 5.43 1.17
Consolidated Net Income / (Loss)
-38 -26 -1.01 6.69 3.97 6.74 11 13 1.12 5.43 1.17
Depreciation Expense
33 44 16 17 18 19 21 20 21 23 22
Amortization Expense
0.84 0.84 0.84 0.83 0.41 0.42 0.43 0.44 0.45 0.45 0.46
Non-Cash Adjustments To Reconcile Net Income
43 33 26 28 26 20 0.13 19 18 -52 -18
Changes in Operating Assets and Liabilities, net
21 -35 0.83 -42 39 -1.97 -23 -2.64 35 56 6.82
Net Cash From Investing Activities
-14 -13 -21 -17 -16 -17 -52 -18 -18 -32 -22
Net Cash From Continuing Investing Activities
-14 -13 -21 -17 -16 -17 -52 -18 -18 -32 -22
Purchase of Property, Plant & Equipment
-14 -13 -21 -17 -16 -17 -22 -18 -18 -16 -22
Acquisitions
- - 0.00 - - - -30 - - -13 0.00
Net Cash From Financing Activities
-14 -126 -161 -0.86 -172 -3.53 -105 -51 -66 -13 -16
Net Cash From Continuing Financing Activities
-14 -126 -161 -0.86 -172 -3.53 -105 -51 -66 -13 -16
Repayment of Debt
-1.76 0.00 -3.52 -1.76 -636 - -1.25 -1.25 -1.25 -1.25 -1.25
Repurchase of Common Equity
-7.71 -78 -153 - -5.43 -0.19 -100 -46 -61 -9.43 -13
Other Financing Activities, net
-4.24 -49 -4.23 0.04 -2.29 -4.25 -3.76 -4.55 -3.51 -2.60 -2.49

Annual Balance Sheets for GoodRx

This table presents GoodRx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
387 1,470 1,608 1,605 1,589 1,388 1,404
Total Current Assets
87 1,086 1,089 920 873 659 643
Cash & Equivalents
26 969 941 757 672 448 262
Accounts Receivable
48 69 118 117 144 146 236
Prepaid Expenses
12 46 30 45 57 42 47
Other Current Assets
- - - - - 23 98
Plant, Property, & Equipment, net
1.86 23 22 20 16 13 12
Total Noncurrent Assets
298 361 497 665 700 716 749
Goodwill
236 261 330 412 411 411 430
Intangible Assets
26 57 134 190 156 177 203
Noncurrent Deferred & Refundable Income Taxes
2.21 13 - 0.00 65 77 57
Other Noncurrent Operating Assets
33 30 34 63 68 51 58
Total Liabilities & Shareholders' Equity
387 1,470 1,608 1,605 1,589 1,388 1,404
Total Liabilities
737 759 776 790 827 663 788
Total Current Liabilities
33 60 81 76 123 124 246
Short-Term Debt
7.03 7.03 7.03 7.03 8.79 5.00 5.00
Accounts Payable
7.85 10 18 18 36 14 19
Accrued Expenses
16 38 51 48 71 83 87
Other Current Liabilities
2.94 4.54 5.85 4.07 6.18 21 135
Total Noncurrent Liabilities
704 699 695 713 704 540 542
Long-Term Debt
664 660 656 652 648 487 483
Other Noncurrent Operating Liabilities
40 39 39 62 57 53 59
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-1,088 711 832 815 762 725 616
Total Preferred & Common Equity
-1,088 711 832 815 762 725 616
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-1,088 711 832 815 762 725 616
Common Stock
9.25 2,102 2,247 2,263 2,219 2,166 2,027
Retained Earnings
-1,097 -1,390 -1,416 -1,449 -1,457 -1,441 -1,411

Quarterly Balance Sheets for GoodRx

This table presents GoodRx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets
1,567 1,612 1,692 1,708 1,454 1,475 1,355 1,295 1,319 1,326 2,021
Total Current Assets
878 907 919 969 733 751 627 540 551 566 1,266
Cash & Equivalents
729 761 762 795 533 525 424 301 281 274 236
Accounts Receivable
121 116 123 121 145 162 131 160 189 204 233
Prepaid Expenses
29 29 34 53 55 64 72 79 80 88 45
Other Current Assets
- - - - - - - - - - 754
Plant, Property, & Equipment, net
22 19 18 17 15 14 14 12 11 11 12
Total Noncurrent Assets
666 686 755 722 706 710 714 744 757 749 743
Goodwill
415 412 412 412 411 411 411 422 422 422 430
Intangible Assets
197 197 202 181 162 168 174 199 204 205 201
Noncurrent Deferred & Refundable Income Taxes
- - 63 58 65 65 66 77 77 69 53
Other Noncurrent Operating Assets
54 76 78 71 68 67 64 46 55 53 58
Total Liabilities & Shareholders' Equity
1,567 1,612 1,692 1,708 1,454 1,475 1,355 1,295 1,319 1,326 2,021
Total Liabilities
779 784 797 827 823 806 658 641 676 725 1,399
Total Current Liabilities
85 69 83 118 117 102 114 103 131 182 859
Short-Term Debt
7.03 7.03 7.03 7.03 7.03 7.03 3.75 5.00 5.00 5.00 5.00
Accounts Payable
11 12 6.80 33 34 17 12 15 25 29 15
Accrued Expenses
61 48 66 75 71 73 93 78 96 143 84
Other Current Liabilities
6.06 1.83 2.73 3.33 5.13 5.39 5.54 5.56 4.82 4.76 756
Total Noncurrent Liabilities
694 715 714 709 706 704 544 538 545 543 540
Long-Term Debt
653 651 650 649 647 646 488 486 485 484 482
Other Noncurrent Operating Liabilities
40 64 64 60 60 58 56 52 60 59 58
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
788 827 895 881 631 669 696 654 643 601 622
Total Preferred & Common Equity
788 827 895 881 631 669 696 654 643 601 622
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
788 827 895 881 631 669 696 654 643 601 622
Common Stock
2,235 2,279 2,288 2,313 2,089 2,121 2,144 2,084 2,060 2,017 2,031
Retained Earnings
-1,447 -1,452 -1,393 -1,432 -1,458 -1,452 -1,448 -1,430 -1,417 -1,416 -1,409

Annual Metrics And Ratios for GoodRx

This table displays calculated financial ratios and metrics derived from GoodRx's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - -
Revenue Growth
0.00% 55.59% 41.85% 35.36% 2.83% -2.13% 5.61% 0.57%
EBITDA Growth
0.00% 74.05% -265.25% 120.24% 15.45% 34.90% 68.95% 29.56%
EBIT Growth
0.00% 76.98% -301.70% 104.86% -87.04% -1,884.52% 303.73% 39.60%
NOPAT Growth
0.00% 72.03% -273.60% 104.86% -87.04% -1,653.91% 281.46% 37.31%
Net Income Growth
0.00% 73.09% -487.36% 91.40% -29.99% 72.99% 284.82% 85.72%
EPS Growth
0.00% 50.00% -694.44% 94.39% -33.33% 75.00% 300.00% 125.00%
Operating Cash Flow Growth
0.00% 84.05% 57.70% 36.12% -17.90% -5.78% 32.97% -8.69%
Free Cash Flow Firm Growth
0.00% 0.00% -66.77% 55.01% -17.78% 69.98% 125.60% -321.81%
Invested Capital Growth
0.00% 0.00% 38.19% 36.09% 29.46% 4.14% 2.93% 9.72%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 8.71% -3.66% 1.70% 0.25% -0.47%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% 119.32% -7.98% 5.31% 9.33% 5.61%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 104.50% -85.22% -344.21% 136.49% 6.29%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 104.50% -85.22% -286.81% 66.81% -3.92%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 91.10% 53.61% -159.01% 201.05% -4.14%
EPS Q/Q Growth
0.00% 0.00% 0.00% 93.94% 50.00% -166.67% 233.33% 12.50%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -1.25% 24.31% -10.89% -10.38% 18.63% -6.59%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% -43.25% -76.28% 1,049.55% -742.60%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% -7.49% -0.41% 0.54% 0.53% 3.24%
Profitability Metrics
- - - - - - - -
Gross Margin
97.58% 96.39% 94.63% 93.73% 91.51% 91.08% 93.91% 92.77%
EBITDA Margin
35.38% 39.58% -46.11% 6.89% 7.74% 10.67% 17.07% 21.99%
Operating Margin
30.96% 35.98% -50.07% 1.80% 0.23% -3.60% 8.31% 10.98%
EBIT Margin
30.96% 35.21% -50.07% 1.80% 0.23% -4.13% 7.97% 11.07%
Profit (Net Income) Margin
17.55% 19.53% -53.32% -3.39% -4.28% -1.18% 2.07% 3.82%
Tax Burden Percent
83.66% 91.35% 96.76% 248.15% 141.31% 15.96% 52.10% 53.84%
Interest Burden Percent
67.77% 60.70% 110.05% -75.91% -1,336.65% 179.18% 49.79% 64.09%
Effective Tax Rate
16.34% 20.40% 0.00% 0.00% 0.00% 0.00% 47.90% 46.16%
Return on Invested Capital (ROIC)
0.00% 75.55% -55.07% 1.95% 0.19% -2.59% 4.53% 5.85%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 64.58% -114.22% 13.84% 18.27% -20.17% -125.48% -6.50%
Return on Net Nonoperating Assets (RNNOA)
0.00% -118.80% -107.70% -5.23% -4.18% 1.46% -2.33% -1.31%
Return on Equity (ROE)
0.00% -43.24% -162.77% -3.27% -3.99% -1.12% 2.21% 4.54%
Cash Return on Invested Capital (CROIC)
0.00% -124.45% -87.13% -28.62% -25.48% -6.64% 1.64% -3.42%
Operating Return on Assets (OROA)
0.00% 35.34% -29.70% 0.87% 0.11% -1.94% 4.25% 6.32%
Return on Assets (ROA)
0.00% 19.60% -31.62% -1.64% -2.04% -0.56% 1.10% 2.18%
Return on Common Equity (ROCE)
0.00% -134.16% 169.75% -3.27% -3.99% -1.12% 2.21% 4.54%
Return on Equity Simple (ROE_SIMPLE)
0.00% -6.97% -41.28% -3.04% -4.03% -1.16% 2.26% 0.00%
Net Operating Profit after Tax (NOPAT)
65 111 -193 9.38 1.22 -19 34 47
NOPAT Margin
25.90% 28.64% -35.05% 1.26% 0.16% -2.52% 4.33% 5.91%
Net Nonoperating Expense Percent (NNEP)
0.00% 10.97% 59.15% -11.88% -18.08% 17.59% 130.01% 12.35%
Return On Investment Capital (ROIC_SIMPLE)
- - - - 0.08% -1.33% 2.82% 4.26%
Cost of Revenue to Revenue
2.42% 3.61% 5.37% 6.27% 8.49% 8.92% 6.09% 7.23%
SG&A Expenses to Revenue
3.35% 3.78% 83.79% 20.75% 18.89% 16.73% 14.88% 14.30%
R&D to Revenue
17.59% 7.55% 11.23% 16.88% 18.67% 18.11% 15.62% 15.19%
Operating Expenses to Revenue
66.62% 60.41% 144.69% 91.93% 91.28% 94.68% 85.60% 81.79%
Earnings before Interest and Taxes (EBIT)
77 137 -276 13 1.74 -31 63 88
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
88 154 -254 51 59 80 135 175
Valuation Ratios
- - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 22.13 15.67 2.27 3.57 2.45 1.49
Price to Tangible Book Value (P/TBV)
0.00 0.00 40.01 35.40 8.68 13.96 12.94 0.00
Price to Revenue (P/Rev)
4.58 2.94 28.59 17.49 2.41 3.63 2.24 1.15
Price to Earnings (P/E)
80.30 17.30 0.00 0.00 0.00 0.00 108.13 30.22
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
1.25% 5.78% 0.00% 0.00% 0.00% 0.00% 0.92% 3.31%
Enterprise Value to Invested Capital (EV/IC)
0.00 8.58 37.96 23.05 2.44 3.63 2.36 1.36
Enterprise Value to Revenue (EV/Rev)
0.00 6.50 28.04 17.11 2.28 3.61 2.29 1.44
Enterprise Value to EBITDA (EV/EBITDA)
0.00 16.43 0.00 248.24 29.46 33.80 13.43 6.54
Enterprise Value to EBIT (EV/EBIT)
0.00 18.46 0.00 951.60 1,005.70 0.00 28.74 13.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 22.70 0.00 1,359.43 1,436.71 0.00 52.93 24.34
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 30.31 117.55 71.36 11.91 19.56 9.87 6.83
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 146.03 0.00
Leverage & Solvency
- - - - - - - -
Debt to Equity
0.00 -1.91 0.94 0.80 0.81 0.86 0.68 0.79
Long-Term Debt to Equity
0.00 -1.89 0.93 0.79 0.80 0.85 0.67 0.78
Financial Leverage
0.00 -1.84 0.94 -0.38 -0.23 -0.07 0.02 0.20
Leverage Ratio
0.00 -1.10 5.15 1.99 1.95 2.03 2.00 2.08
Compound Leverage Factor
0.00 -0.67 5.66 -1.51 -26.08 3.63 1.00 1.33
Debt to Total Capital
0.00% 209.43% 48.39% 44.35% 44.71% 46.28% 40.42% 44.21%
Short-Term Debt to Total Capital
0.00% 2.19% 0.51% 0.47% 0.48% 0.62% 0.41% 0.45%
Long-Term Debt to Total Capital
0.00% 207.24% 47.88% 43.88% 44.23% 45.66% 40.01% 43.75%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 230.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% -339.50% 51.61% 55.65% 55.29% 53.72% 59.58% 55.79%
Debt to EBITDA
0.00 4.37 -2.63 12.90 11.10 8.20 3.64 2.79
Net Debt to EBITDA
0.00 4.20 1.20 -5.41 -1.66 -0.20 0.32 1.29
Long-Term Debt to EBITDA
0.00 4.32 -2.60 12.76 10.99 8.09 3.60 2.76
Debt to NOPAT
0.00 6.03 -3.46 70.64 541.53 -34.73 14.33 10.37
Net Debt to NOPAT
0.00 5.80 1.58 -29.65 -80.83 0.84 1.26 4.81
Long-Term Debt to NOPAT
0.00 5.97 -3.42 69.89 535.75 -34.26 14.19 10.26
Altman Z-Score
0.00 -0.71 11.72 10.09 1.25 1.66 1.33 0.41
Noncontrolling Interest Sharing Ratio
0.00% -210.23% 204.29% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - -
Current Ratio
0.00 2.59 18.24 13.42 12.05 7.12 5.32 2.61
Quick Ratio
0.00 2.22 17.42 13.06 11.46 6.66 4.80 2.02
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -183 -305 -137 -162 -49 12 -28
Operating Cash Flow to CapEx
1,308.65% 1,448.70% 366.63% 518.85% 265.84% 247.99% 261.41% 226.84%
Free Cash Flow to Firm to Interest Expense
0.00 -3.36 -10.94 -5.81 -4.73 -0.86 0.23 -0.65
Operating Cash Flow to Interest Expense
1.81 1.53 4.71 7.56 4.29 2.44 3.34 3.94
Operating Cash Flow Less CapEx to Interest Expense
1.67 1.42 3.42 6.10 2.67 1.45 2.06 2.20
Efficiency Ratios
- - - - - - - -
Asset Turnover
0.00 1.00 0.59 0.48 0.48 0.47 0.53 0.57
Accounts Receivable Turnover
0.00 8.07 9.43 7.98 6.52 5.75 5.47 4.18
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 208.72 44.20 33.38 37.00 41.97 55.42 63.92
Accounts Payable Turnover
0.00 1.79 3.26 3.36 3.70 2.48 1.91 3.43
Days Sales Outstanding (DSO)
0.00 45.25 38.73 45.74 56.00 63.43 66.69 87.41
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 204.45 111.90 108.57 98.71 147.16 190.78 106.28
Cash Conversion Cycle (CCC)
0.00 -159.20 -73.18 -62.84 -42.71 -83.74 -124.09 -18.87
Capital & Investment Metrics
- - - - - - - -
Invested Capital
0.00 294 407 553 716 746 768 843
Invested Capital Turnover
0.00 2.64 1.57 1.55 1.21 1.03 1.05 0.99
Increase / (Decrease) in Invested Capital
0.00 294 112 147 163 30 22 75
Enterprise Value (EV)
0.00 2,524 15,439 12,757 1,748 2,705 1,816 1,146
Market Capitalization
1,142 1,142 15,744 13,035 1,846 2,721 1,772 920
Book Value per Share
$0.00 ($4.80) $1.82 $2.09 $2.06 $1.88 $1.90 $1.82
Tangible Book Value per Share
$0.00 ($5.96) $1.01 $0.92 $0.54 $0.48 $0.36 ($0.05)
Total Capital
0.00 320 1,378 1,495 1,474 1,418 1,216 1,105
Total Debt
0.00 671 667 663 659 656 492 488
Total Long-Term Debt
0.00 664 660 656 652 648 487 483
Net Debt
0.00 645 -305 -278 -98 -16 43 226
Capital Expenditures (CapEx)
3.46 5.75 36 34 55 56 70 74
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 34 62 74 93 87 92 140
Debt-free Net Working Capital (DFNWC)
0.00 60 1,034 1,015 850 759 540 402
Net Working Capital (NWC)
0.00 53 1,027 1,008 843 750 535 397
Net Nonoperating Expense (NNE)
21 35 101 35 34 -10 18 17
Net Nonoperating Obligations (NNO)
0.00 645 -305 -278 -98 -16 43 226
Total Depreciation and Amortization (D&A)
11 17 22 38 58 111 72 87
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 8.81% 11.30% 9.88% 12.16% 11.56% 11.61% 17.60%
Debt-free Net Working Capital to Revenue
0.00% 15.52% 187.73% 136.13% 110.94% 101.17% 68.20% 50.46%
Net Working Capital to Revenue
0.00% 13.71% 186.46% 135.19% 110.02% 100.00% 67.57% 49.83%
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($1.07) ($0.06) ($0.08) ($0.02) $0.04 $0.09
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 274.70M 409.98M 412.86M 410.32M 385.74M 356.33M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($1.07) ($0.06) ($0.08) ($0.02) $0.04 $0.09
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 274.70M 409.98M 412.86M 410.32M 392.17M 356.97M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 392.13M 400.85M 397.57M 395.00M 383.61M 342.57M
Normalized Net Operating Profit after Tax (NOPAT)
65 111 -193 9.38 1.22 -19 34 47
Normalized NOPAT Margin
25.90% 28.64% -35.05% 1.26% 0.16% -2.52% 4.33% 5.91%
Pre Tax Income Margin
20.98% 21.37% -55.10% -1.37% -3.03% -7.41% 3.97% 7.10%
Debt Service Ratios
- - - - - - - -
EBIT to Interest Expense
3.08 2.51 -9.88 0.57 0.05 -0.55 1.15 2.07
NOPAT to Interest Expense
2.58 2.04 -6.91 0.40 0.04 -0.33 0.62 1.11
EBIT Less CapEx to Interest Expense
2.95 2.41 -11.16 -0.89 -1.56 -1.53 -0.13 0.33
NOPAT Less CapEx to Interest Expense
2.44 1.94 -8.20 -1.06 -1.58 -1.32 -0.66 -0.63
Payout Ratios
- - - - - - - -
Dividend Payout Ratio
3,074.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
3,074.36% 0.00% -1.68% 0.00% -309.86% -1,172.46% 969.16% 710.84%

Quarterly Metrics And Ratios for GoodRx

This table displays calculated financial ratios and metrics derived from GoodRx's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
- - - - - - - - - - 342,574,498.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 342,574,498.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 0.00
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-3.93% 6.81% 7.55% 5.76% 8.50% 0.99% 2.57% 1.23% 0.40% -1.91% -4.42%
EBITDA Growth
-632.89% 44.38% -4.44% 6.86% 635.80% 44.09% 85.11% 26.55% 2.24% 22.78% -18.91%
EBIT Growth
-157.94% -1,152.85% -22.26% 8.58% 143.79% 199.41% 216.76% 38.36% -17.62% 24.77% -40.08%
NOPAT Growth
-143.94% -1,152.85% -145.79% -87.19% 137.18% 183.90% 160.99% 53.93% -73.11% -19.27% -81.27%
Net Income Growth
7.76% -1,211.82% 69.33% -88.61% 110.30% 126.05% 1,195.34% 91.86% -71.78% -19.51% -89.42%
EPS Growth
10.00% -500.00% 100.00% -85.71% 111.11% 116.67% 0.00% 100.00% -100.00% 100.00% -100.00%
Operating Cash Flow Growth
78.67% -50.22% 31.89% -67.52% 44.12% 181.97% -77.90% 411.08% -12.48% -26.50% 25.76%
Free Cash Flow Firm Growth
62.56% 73.76% 59.95% -90.66% 75.96% 73.79% -46.52% -935.84% -316.95% -493.06% 65.56%
Invested Capital Growth
3.15% 4.14% 3.77% 0.89% 2.95% 2.93% 12.34% 6.84% 6.85% 9.72% 3.49%
Revenue Q/Q Growth
-5.12% 9.27% 0.63% 1.38% -2.67% 1.71% 2.21% 0.05% -3.47% -0.63% -0.40%
EBITDA Q/Q Growth
-118.90% 492.72% -7.66% 55.91% -5.24% 5.61% 18.64% 6.59% -23.44% 26.82% -21.65%
EBIT Q/Q Growth
-321.38% 54.88% 140.36% 169.31% -10.72% 2.44% 28.60% 17.63% -46.84% 55.15% -38.24%
NOPAT Q/Q Growth
-130.09% 52.29% -98.55% 144.95% -12.70% 7.67% 44.34% 13.45% -84.75% 223.28% -66.50%
Net Income Q/Q Growth
-165.48% 32.80% 96.10% 763.43% -40.77% 69.99% 63.98% 16.21% -91.29% 384.81% -78.45%
EPS Q/Q Growth
-164.29% 33.33% 100.00% 0.00% -50.00% 0.00% 200.00% 33.33% -100.00% 0.00% -100.00%
Operating Cash Flow Q/Q Growth
101.80% -73.67% 168.38% -77.22% 795.39% -48.49% -78.96% 426.72% 53.33% -56.74% -64.01%
Free Cash Flow Firm Q/Q Growth
-204.70% 14.20% -24.10% 108.38% -369.36% 6.46% -593.74% 52.18% -34.37% -33.05% 59.72%
Invested Capital Q/Q Growth
-6.08% 0.54% 0.71% 6.08% -4.16% 0.53% 9.92% 0.89% -4.16% 3.24% 3.68%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
89.60% 92.29% 93.70% 94.08% 100.00% 87.98% 93.42% 93.43% 93.15% 91.03% 89.61%
EBITDA Margin
-3.70% 13.30% 12.21% 18.78% 18.28% 18.98% 22.03% 23.48% 18.62% 23.76% 18.69%
Operating Margin
-21.30% -9.30% 3.73% 9.91% 10.45% 9.15% 11.52% 13.20% 7.46% 11.65% 7.22%
EBIT Margin
-22.52% -9.30% 3.73% 9.91% 9.09% 9.15% 11.52% 13.54% 7.46% 11.65% 7.22%
Profit (Net Income) Margin
-21.39% -13.16% -0.51% 3.34% 2.03% 3.39% 5.45% 6.32% 0.57% 2.79% 0.60%
Tax Burden Percent
82.61% 105.01% -344.37% 57.48% 48.88% 59.08% 66.31% 65.60% 18.34% 38.22% 20.73%
Interest Burden Percent
114.98% 134.71% 3.97% 58.59% 45.71% 62.76% 71.29% 71.18% 41.72% 62.57% 40.25%
Effective Tax Rate
0.00% 0.00% 444.37% 42.52% 51.12% 40.92% 33.69% 34.40% 81.66% 61.78% 79.27%
Return on Invested Capital (ROIC)
-15.05% -6.68% -13.30% 5.56% 5.36% 5.66% 7.63% 8.40% 1.39% 4.40% 1.37%
ROIC Less NNEP Spread (ROIC-NNEP)
-3.84% 16.22% 271.48% -36.37% 22.15% -23.37% 4.76% 5.58% 0.28% 2.00% 0.59%
Return on Net Nonoperating Assets (RNNOA)
0.48% -1.17% 3.19% -0.52% -1.01% -0.43% 1.15% 1.43% 0.06% 0.40% 0.20%
Return on Equity (ROE)
-14.57% -7.85% -10.11% 5.04% 4.36% 5.23% 8.78% 9.83% 1.45% 4.81% 1.58%
Cash Return on Invested Capital (CROIC)
-3.77% -6.64% -6.63% -3.47% -0.17% 1.64% -5.52% 0.07% -0.41% -3.42% 0.67%
Operating Return on Assets (OROA)
-10.15% -4.37% 1.86% 4.85% 4.69% 4.87% 6.68% 7.75% 4.46% 6.65% 3.43%
Return on Assets (ROA)
-9.64% -6.18% -0.25% 1.63% 1.05% 1.81% 3.16% 3.62% 0.34% 1.59% 0.29%
Return on Common Equity (ROCE)
-14.57% -7.85% -10.11% 5.04% 4.36% 5.23% 8.78% 9.83% 1.45% 4.81% 1.58%
Return on Equity Simple (ROE_SIMPLE)
1.71% 0.00% -1.04% -8.77% -2.33% 0.00% 4.35% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-27 -13 -25 11 9.97 11 16 18 2.68 8.67 2.90
NOPAT Margin
-14.91% -6.51% -12.85% 5.70% 5.11% 5.41% 7.64% 8.66% 1.37% 4.45% 1.50%
Net Nonoperating Expense Percent (NNEP)
-11.21% -22.90% -284.78% 41.93% -16.79% 29.03% 2.87% 2.82% 1.10% 2.41% 0.79%
Return On Investment Capital (ROIC_SIMPLE)
- -0.90% - - - 0.88% 1.35% 1.55% 0.25% 0.79% 0.26%
Cost of Revenue to Revenue
10.40% 7.71% 6.30% 5.92% 0.00% 12.02% 6.58% 6.57% 6.85% 8.97% 10.39%
SG&A Expenses to Revenue
19.63% 15.44% 20.77% 13.75% 13.12% 11.86% 14.60% 13.98% 16.33% 12.29% 13.82%
R&D to Revenue
22.01% 16.29% 15.67% 15.38% 15.44% 15.98% 15.34% 14.74% 15.82% 14.86% 15.55%
Operating Expenses to Revenue
110.90% 101.59% 89.97% 84.17% 89.55% 78.82% 81.90% 80.22% 85.70% 79.39% 82.39%
Earnings before Interest and Taxes (EBIT)
-41 -18 7.38 20 18 18 23 28 15 23 14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-6.66 26 24 38 36 38 45 48 36 46 36
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.54 3.57 4.44 4.37 3.78 2.45 2.59 2.77 2.45 1.49 1.08
Price to Tangible Book Value (P/TBV)
7.78 13.96 48.19 32.22 23.57 12.94 50.21 101.88 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.04 3.63 3.67 3.78 3.33 2.24 2.12 2.22 1.84 1.15 0.85
Price to Earnings (P/E)
149.04 0.00 0.00 0.00 0.00 108.13 59.46 51.41 46.28 30.22 32.66
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.67% 0.00% 0.00% 0.00% 0.00% 0.92% 1.68% 1.95% 2.16% 3.31% 3.06%
Enterprise Value to Invested Capital (EV/IC)
2.83 3.63 3.89 3.83 3.54 2.36 2.23 2.33 2.06 1.36 1.06
Enterprise Value to Revenue (EV/Rev)
2.85 3.61 3.83 3.94 3.42 2.29 2.36 2.48 2.10 1.44 1.17
Enterprise Value to EBITDA (EV/EBITDA)
27.64 33.80 37.07 37.56 21.84 13.43 11.88 11.85 10.16 6.54 5.56
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 101.09 28.74 22.99 22.39 20.31 13.00 11.82
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 131.34 52.93 38.65 36.08 34.38 24.34 26.16
Enterprise Value to Operating Cash Flow (EV/OCF)
13.61 19.56 19.68 23.78 17.42 9.87 12.48 10.43 9.38 6.83 5.42
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 146.03 0.00 3,492.44 0.00 0.00 159.40
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.74 0.86 1.04 0.98 0.71 0.68 0.75 0.76 0.81 0.79 0.78
Long-Term Debt to Equity
0.74 0.85 1.02 0.96 0.70 0.67 0.74 0.75 0.81 0.78 0.78
Financial Leverage
-0.12 -0.07 0.01 0.01 -0.05 0.02 0.24 0.26 0.22 0.20 0.35
Leverage Ratio
1.96 2.03 2.10 2.02 1.94 2.00 2.14 2.13 2.07 2.08 2.60
Compound Leverage Factor
2.26 2.73 0.08 1.19 0.89 1.26 1.52 1.52 0.86 1.30 1.05
Debt to Total Capital
42.66% 46.28% 50.88% 49.37% 41.37% 40.42% 42.86% 43.25% 44.88% 44.21% 43.94%
Short-Term Debt to Total Capital
0.46% 0.62% 0.55% 0.53% 0.32% 0.41% 0.44% 0.44% 0.46% 0.45% 0.45%
Long-Term Debt to Total Capital
42.21% 45.66% 50.33% 48.84% 41.05% 40.01% 42.42% 42.80% 44.42% 43.75% 43.48%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
57.34% 53.72% 49.12% 50.63% 58.63% 59.58% 57.14% 56.75% 55.12% 55.79% 56.06%
Debt to EBITDA
8.63 8.20 8.28 8.03 3.97 3.64 3.10 2.92 2.95 2.79 2.94
Net Debt to EBITDA
-1.83 -0.20 1.53 1.57 0.55 0.32 1.20 1.24 1.30 1.29 1.52
Long-Term Debt to EBITDA
8.54 8.09 8.19 7.94 3.94 3.60 3.07 2.89 2.92 2.76 2.91
Debt to NOPAT
-134.17 -34.73 -30.19 -31.76 23.89 14.33 10.08 8.90 9.98 10.37 13.81
Net Debt to NOPAT
28.47 0.84 -5.56 -6.22 3.29 1.26 3.90 3.79 4.40 4.81 7.13
Long-Term Debt to NOPAT
-132.74 -34.26 -29.87 -31.42 23.71 14.19 9.98 8.80 9.88 10.26 13.67
Altman Z-Score
1.40 1.69 1.69 1.90 1.98 1.23 1.12 1.13 0.71 0.25 -0.03
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
8.23 7.12 6.29 7.32 5.48 5.32 5.23 4.21 3.11 2.61 1.47
Quick Ratio
7.77 6.66 5.82 6.70 4.85 4.80 4.46 3.59 2.62 2.02 0.55
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-49 -42 -53 4.42 -12 -11 -77 -37 -50 -66 -27
Operating Cash Flow to CapEx
441.64% 123.28% 206.58% 56.31% 547.71% 268.82% 43.03% 270.71% 422.37% 207.76% 54.69%
Free Cash Flow to Firm to Interest Expense
-3.36 -2.87 -3.60 0.30 -0.82 -0.98 -7.25 -3.44 -4.58 -6.35 -2.72
Operating Cash Flow to Interest Expense
4.09 1.07 2.91 0.67 6.02 3.94 0.88 4.62 7.02 3.16 1.21
Operating Cash Flow Less CapEx to Interest Expense
3.17 0.20 1.50 -0.52 4.92 2.47 -1.17 2.91 5.36 1.64 -1.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.45 0.47 0.50 0.49 0.52 0.53 0.58 0.57 0.60 0.57 0.48
Accounts Receivable Turnover
6.10 5.75 5.85 5.44 6.27 5.47 5.23 4.56 4.79 4.18 4.01
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
37.67 41.97 44.81 47.82 51.82 55.42 59.39 63.41 64.31 63.92 67.76
Accounts Payable Turnover
3.16 2.48 2.73 4.92 1.74 1.91 2.01 2.39 2.55 3.43 4.32
Days Sales Outstanding (DSO)
59.87 63.43 62.38 67.14 58.18 66.69 69.78 80.04 76.26 87.41 90.99
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
115.55 147.16 133.63 74.21 209.24 190.78 181.26 152.57 143.40 106.28 84.42
Cash Conversion Cycle (CCC)
-55.68 -83.74 -71.24 -7.07 -151.06 -124.09 -111.48 -72.53 -67.15 -18.87 6.58
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
742 746 751 797 764 768 844 852 816 843 874
Invested Capital Turnover
1.01 1.03 1.04 0.98 1.05 1.05 1.00 0.97 1.01 0.99 0.92
Increase / (Decrease) in Invested Capital
23 30 27 7.01 22 22 93 55 52 75 29
Enterprise Value (EV)
2,101 2,705 2,925 3,054 2,701 1,816 1,882 1,987 1,685 1,146 923
Market Capitalization
2,240 2,721 2,804 2,927 2,633 1,772 1,692 1,779 1,470 920 671
Book Value per Share
$2.22 $1.88 $1.60 $1.78 $1.84 $1.90 $1.71 $1.80 $1.73 $1.82 $1.82
Tangible Book Value per Share
$0.72 $0.48 $0.15 $0.24 $0.29 $0.36 $0.09 $0.05 ($0.07) ($0.05) ($0.03)
Total Capital
1,537 1,418 1,285 1,322 1,188 1,216 1,145 1,133 1,090 1,105 1,109
Total Debt
656 656 654 653 491 492 491 490 489 488 487
Total Long-Term Debt
649 648 647 646 488 487 486 485 484 483 482
Net Debt
-139 -16 120 128 68 43 190 209 216 226 252
Capital Expenditures (CapEx)
14 13 21 17 16 17 22 18 18 16 22
Debt-free, Cash-free Net Working Capital (DFCFNWC)
63 87 90 130 92 92 141 143 115 140 177
Debt-free Net Working Capital (DFNWC)
858 759 623 655 516 540 442 425 389 402 412
Net Working Capital (NWC)
851 750 616 648 512 535 437 420 384 397 407
Net Nonoperating Expense (NNE)
12 13 -24 4.73 6.01 4.00 4.45 4.74 1.56 3.25 1.74
Net Nonoperating Obligations (NNO)
-139 -16 120 128 68 43 190 209 216 226 252
Total Depreciation and Amortization (D&A)
34 44 17 18 18 20 21 20 22 24 22
Debt-free, Cash-free Net Working Capital to Revenue
8.59% 11.56% 11.78% 16.80% 11.69% 11.61% 17.66% 17.93% 14.38% 17.60% 22.41%
Debt-free Net Working Capital to Revenue
116.34% 101.17% 81.57% 84.52% 65.31% 68.20% 55.41% 53.10% 48.54% 50.46% 52.33%
Net Working Capital to Revenue
115.39% 100.00% 80.65% 83.61% 64.83% 67.57% 54.78% 52.47% 47.92% 49.83% 51.69%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.09) ($0.06) $0.00 $0.02 $0.01 $0.01 $0.03 $0.04 $0.00 $0.02 $0.00
Adjusted Weighted Average Basic Shares Outstanding
413.44M 410.32M 390.05M 376.25M 379.67M 385.74M 379.20M 356.62M 346.78M 356.33M 340.53M
Adjusted Diluted Earnings per Share
($0.09) ($0.06) $0.00 $0.02 $0.01 $0.01 $0.03 $0.04 $0.00 $0.02 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
413.44M 410.32M 390.05M 384.73M 388.50M 392.17M 379.66M 357.16M 347.81M 356.97M 341.42M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
406.13M 395.00M 375.21M 379.45M 381.14M 383.61M 357.17M 347.45M 339.43M 342.57M 338.68M
Normalized Net Operating Profit after Tax (NOPAT)
-27 -13 5.17 11 14 11 16 18 10 16 9.81
Normalized NOPAT Margin
-14.91% -6.51% 2.61% 5.70% 7.32% 5.41% 7.64% 8.66% 5.22% 8.15% 5.05%
Pre Tax Income Margin
-25.90% -12.53% 0.15% 5.81% 4.15% 5.75% 8.21% 9.64% 3.11% 7.29% 2.91%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-2.75 -1.23 0.50 1.36 1.23 1.60 2.20 2.56 1.35 2.18 1.43
NOPAT to Interest Expense
-1.82 -0.86 -1.74 0.78 0.69 0.95 1.46 1.64 0.25 0.83 0.30
EBIT Less CapEx to Interest Expense
-3.68 -2.10 -0.90 0.18 0.13 0.14 0.14 0.86 -0.31 0.66 -0.78
NOPAT Less CapEx to Interest Expense
-2.75 -1.73 -3.14 -0.40 -0.41 -0.52 -0.60 -0.07 -1.41 -0.69 -1.92
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
173.99% -1,172.46% -3,760.18% -406.90% -1,458.06% 969.16% 370.87% 437.88% 652.30% 710.84% 627.76%

Financials Breakdown Chart

Key Financial Trends

GoodRx Holdings, Inc. (GDRX) has shown relatively steady operating economics and cash flow across the four-year window provided, with a pattern of high gross margins and modest quarterly profits. Below are the key trends drawn from the quarterly income statements, cash flow statements, and balance sheets (latest quarter shown is Q4 2025).

  • Consistently very high gross margins around 90% across the period (example: Q4 2025 Total Revenue $194.8M, Total Gross Profit $177.3M, implying roughly 91% gross margin), signaling durable product economics even as revenue fluctuates.
  • Positive quarterly net income in multiple 2025 quarters, highlighting an improving profitability trajectory (examples: Q1 2025 Net Income attributable to common shareholders about $11.05M; Q2 2025 about $12.84M; Q4 2025 about $5.43M).
  • Free cash flow generation improves operating cash flow in several quarters (e.g., Q3 2025 Net Cash From Continuing Operating Activities roughly $76.0M; Q4 2024 around $44.7M; Q2 2025 around $49.6M), indicating solid cash generation from core operations.
  • Liquidity remains solid with cash balances in the low-to-mid hundreds of millions in mid-2025 (e.g., about $270M–$281M in cash & equivalents around Q1–Q3 2025), providing liquidity for working capital and ongoing marketing spend.
  • Revenue remains relatively stable, generally in the $190M–$206M range across quarters, implying a stable demand base despite some quarterly variability.
  • Operating expense structure shows persistent high marketing and customer-acquisition spend (Marketing Expense commonly in the upper half of operating expenses), which supports top-line stability but compresses margins if revenue growth slows. This is a neutral dynamic for near-term profitability depending on growth execution.
  • Balance sheet features substantial goodwill and intangible assets, with sizable accumulated earnings changes and negative retained earnings in several periods; this is a neutral factor that could influence impairment risk if growth slows or if accounting changes occur.
  • Financing and investing activity have driven periodic cash burn, with meaningful negative net cash from financing activities in several quarters (examples: Q3 2025 and Q4 2025 show sizable net cash outflows for financing activities due to share repurchases and debt actions), leading to negative net changes in cash in multiple periods.
  • Long-standing accumulated deficit reflected in retained earnings across multiple quarters (retained earnings generally negative in several balance sheets), signaling past losses that the company has not fully offset yet in equity, a caution for longer-term sustainability.
  • Ongoing high marketing and acquisition-related spend relative to revenue keeps net income modest despite healthy gross margins, creating upside risk if the growth cadence decelerates or if indemnified costs rise above expectations.
05/11/26 09:02 AM ETAI Generated. May Contain Errors.

GoodRx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, GoodRx's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

GoodRx's net income appears to be on a downward trend, with a most recent value of $30.44 million in 2025, falling from $43.79 million in 2018. The previous period was $16.39 million in 2024. Check out GoodRx's forecast to explore projected trends and price targets.

GoodRx's total operating income in 2025 was $87.49 million, based on the following breakdown:
  • Total Gross Profit: $739.26 million
  • Total Operating Expenses: $651.76 million

Over the last 7 years, GoodRx's total revenue changed from $249.52 million in 2018 to $796.85 million in 2025, a change of 219.4%.

GoodRx's total liabilities were at $787.80 million at the end of 2025, a 18.7% increase from 2024, and a 6.8% increase since 2019.

In the past 6 years, GoodRx's cash and equivalents has ranged from $26.05 million in 2019 to $968.69 million in 2020, and is currently $261.82 million as of their latest financial filing in 2025.

Over the last 7 years, GoodRx's book value per share changed from 0.00 in 2018 to 1.82 in 2025, a change of 181.6%.



Financial statements for NASDAQ:GDRX last updated on 5/11/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners